Instrument Inactif

Autres langues Fresh Start Private Management Inc Other OTC

Actions

US35804J1025

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

15/05	BioCorRx Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
03/04	BioCorRx Inc. annonce la démission de membres de son conseil d'administration	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

BioCorRx Reports Business Update for the First Quarter of 2024	16/05
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
BioCorRx Inc. Announces Board Resignations	03/04
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	03/04
BioCorRx Reports Business Update for 2023	02/04
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	28/02
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	08/02
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	08/02
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	09/01
BioCorRx Inc. Announces President Changes	05/01
BioCorRx : Material Agreement - Form 8-K	15/12
BioCorRx Inc. announced that it has received $0.2 million in funding	08/12
BioCorRx Reports Business Update for the Third Quarter of 2023	14/11
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
BioCorRx Inc. announced that it has received $0.2 million in funding	10/11
Biocorrx Inc. Announces Management Changes	02/11
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23
BioCorRx Reports Business Update for the Second Quarter of 2023	14/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Fresh Start Private Management Inc Other OTC

Actions

US35804J1025

Autres langues

Filtres